UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 13, 2017

ENTELLUS MEDICAL, INC.

(Exact name of registrant as specified in its charter)

(763) 463-1595

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company  ☒        

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Entellus Medical, Inc. (“Entellus”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 13, 2017. At the Annual Meeting, Entellus’s stockholders considered two proposals, each of which is described in more detail in Entellus’s definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2017.

As of the close of business on April 17, 2017, the record date for the Annual Meeting, there were 21,916,416 shares of Entellus common stock outstanding and entitled to vote at the Annual Meeting. Each share of Entellus common stock was entitled to one vote. Stockholders holding an aggregate of 19,681,419 shares of Entellus common stock entitled to vote at the Annual Meeting, representing 89.8% of the outstanding shares of Entellus common stock as of the record date, and which constituted a quorum thereof, were present in person or represented by proxy at the Annual Meeting.

The final results of such stockholder voting on each proposal brought before the Annual Meeting are set forth below:

Regarding Entellus’s other directors, (i) each of Brian E. Farley and Guido Neels continue to serve as a director for a term ending at Entellus’s 2018 Annual Meeting of Stockholders; and (ii) each of John K. Bakewell, David B. Milne and Robert S. White continue to serve as a director for a term ending at Entellus’s 2019 Annual Meeting of Stockholders.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.